<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01154452</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2011-01412</org_study_id>
    <secondary_id>NCI-2011-01412</secondary_id>
    <secondary_id>CDR0000680558</secondary_id>
    <secondary_id>MSKCC-10049</secondary_id>
    <secondary_id>10-049</secondary_id>
    <secondary_id>8406</secondary_id>
    <secondary_id>N01CM62206</secondary_id>
    <secondary_id>P30CA008748</secondary_id>
    <secondary_id>U01CA069856</secondary_id>
    <nct_id>NCT01154452</nct_id>
  </id_info>
  <brief_title>Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma</brief_title>
  <official_title>A Phase 1B/II Study of GDC-0449 (NSC 747691) in Combination With RO4929097, a Gamma-Secretase Inhibitor (GSI) in Advanced/Metastatic Sarcomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase I/II clinical trial is studying the side effects and best dose of&#xD;
      gamma-secretase/notch signalling pathway inhibitor RO4929097 when given together with&#xD;
      vismodegib and to see how well they work in treating patients with advanced or metastatic&#xD;
      sarcoma. Vismodegib may slow the growth of tumor cells. Gamma-secretase/notch signalling&#xD;
      pathway inhibitor RO4929097 may stop the growth of tumor cells by blocking some of the&#xD;
      enzymes needed for cell growth. Giving vismodegib together with gamma-secretase/notch&#xD;
      signalling pathway inhibitor RO4929097 may be an effective treatment for sarcoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the maximum-tolerated dose (MTD) of gamma-secretase inhibitor RO4929097&#xD;
      (RO4929097) when given in combination with fixed-dose Hedgehog antagonist GDC-0449 (GDC-0449)&#xD;
      which will become the recommended dose for the phase II portion of this study. (Phase Ib) II.&#xD;
      To assess the progression-free survival (PFS) of the combination of RO4929097 with and&#xD;
      without GDC-0449 in two arms of patients with advanced sarcoma. (Phase II)&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To describe the tolerability and adverse event profile of daily GDC-0449 administered&#xD;
      orally in combination with daily RO4929097 administered orally for 21 consecutive days.&#xD;
      (Phase Ib) II. To describe the pharmacokinetics of the combination of the combination of&#xD;
      GDC-0449 and RO4929097. (Phase Ib) III. To assess Response Evaluation Criteria In Solid&#xD;
      Tumors (RECIST) 1.1 overall response rates (complete and partial response [CR+PR]) for&#xD;
      combination therapy. (Phase Ib and II) IV. To conduct pharmacodynamic studies in tissue&#xD;
      biopsies (pre- and post-study) for explorative and hypothesis-generating studies. (Phase Ib&#xD;
      and II) V. To assess overall survival. (Phase II) VI. To further describe the&#xD;
      pharmacokinetics and pharmacodynamics of the combination of GDC-0449 and RO4929097 at the&#xD;
      phase II dose at the continuous schedule. (Phase II) V. To conduct pharmacodynamic studies in&#xD;
      tissue biopsies (pre- and post- study drug[s]) for explorative and hypothesis generating&#xD;
      studies. (Phase II)&#xD;
&#xD;
      OUTLINE: This is a phase I, dose-escalation study of gamma-secretase/notch signalling pathway&#xD;
      inhibitor RO4929097 followed by a phase II study.&#xD;
&#xD;
      PHASE IB:&#xD;
&#xD;
      PART A: Patients receive vismodegib orally (PO) once daily (QD) on days 1-21.&#xD;
&#xD;
      PART B: Beginning within 7 days of finishing part A, patients receive vismodegib PO and&#xD;
      gamma-secretase/notch signalling pathway inhibitor RO4929097 PO QD on days 1-21. Courses&#xD;
      repeat every 21 days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      PHASE II: Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
      ARM I: Patients receive gamma-secretase/notch signalling pathway inhibitor RO4929097 PO QD on&#xD;
      days 1-21.&#xD;
&#xD;
      ARM II: Patients receive vismodegib PO and gamma-secretase/notch signalling pathway inhibitor&#xD;
      RO4929097 PO QD on days 1-21.&#xD;
&#xD;
      In both arms, courses repeat every 21 days in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up for 4 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum-tolerated Dose of Gamma-secretase Inhibitor RO4929097, Defined as the Dose Level Where no More Than 1 Out of 6 Patients Experience DLT at the Highest Dose Level Below the MAD, Graded According to NCI-CTCAE Version 4.0 (Phase Ib)</measure>
    <time_frame>Up to 28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Progression-free survival (PFS) of the combination of RO4929097 with and without GDC-0449 in patients with advanced sarcoma. (Phase II)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate (CR + PR) as Assessed by RECIST 1.1 (Phase Ib and II)</measure>
    <time_frame>Up to 4 months</time_frame>
    <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Adult Alveolar Soft Part Sarcoma</condition>
  <condition>Adult Angiosarcoma</condition>
  <condition>Adult Desmoplastic Small Round Cell Tumor</condition>
  <condition>Adult Epithelioid Hemangioendothelioma</condition>
  <condition>Adult Epithelioid Sarcoma</condition>
  <condition>Adult Extraskeletal Myxoid Chondrosarcoma</condition>
  <condition>Adult Extraskeletal Osteosarcoma</condition>
  <condition>Adult Fibrosarcoma</condition>
  <condition>Adult Leiomyosarcoma</condition>
  <condition>Adult Liposarcoma</condition>
  <condition>Adult Malignant Mesenchymoma</condition>
  <condition>Adult Malignant Peripheral Nerve Sheath Tumor</condition>
  <condition>Adult Rhabdomyosarcoma</condition>
  <condition>Adult Synovial Sarcoma</condition>
  <condition>Adult Unclassified Pleomorphic Sarcoma</condition>
  <condition>Chondrosarcoma</condition>
  <condition>Clear Cell Sarcoma of the Kidney</condition>
  <condition>Conjunctival Kaposi Sarcoma</condition>
  <condition>Dermatofibrosarcoma Protuberans</condition>
  <condition>Gastrointestinal Stromal Tumor</condition>
  <condition>Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor</condition>
  <condition>Metastatic Osteosarcoma</condition>
  <condition>Ovarian Sarcoma</condition>
  <condition>Recurrent Adult Soft Tissue Sarcoma</condition>
  <condition>Recurrent Adult Unclassified Pleomorphic Sarcoma of Bone</condition>
  <condition>Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor</condition>
  <condition>Recurrent Kaposi Sarcoma</condition>
  <condition>Recurrent Osteosarcoma</condition>
  <condition>Recurrent Uterine Corpus Sarcoma</condition>
  <condition>Small Intestine Leiomyosarcoma</condition>
  <condition>Stage III Adult Soft Tissue Sarcoma</condition>
  <condition>Stage III Uterine Sarcoma</condition>
  <condition>Stage IV Adult Soft Tissue Sarcoma</condition>
  <condition>Stage IV Uterine Sarcoma</condition>
  <condition>Unclassified Pleomorphic Sarcoma of Bone</condition>
  <arm_group>
    <arm_group_label>Arm I (gamma-secretase inhibitor RO4929097)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO QD on days 1-21.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (vismodegib and gamma-secretase inhibitor RO4929097)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive vismodegib PO and gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO QD on days 1-21.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gamma-Secretase Inhibitor RO4929097</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (gamma-secretase inhibitor RO4929097)</arm_group_label>
    <arm_group_label>Arm II (vismodegib and gamma-secretase inhibitor RO4929097)</arm_group_label>
    <other_name>RO4929097</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (gamma-secretase inhibitor RO4929097)</arm_group_label>
    <arm_group_label>Arm II (vismodegib and gamma-secretase inhibitor RO4929097)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (gamma-secretase inhibitor RO4929097)</arm_group_label>
    <arm_group_label>Arm II (vismodegib and gamma-secretase inhibitor RO4929097)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vismodegib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm II (vismodegib and gamma-secretase inhibitor RO4929097)</arm_group_label>
    <other_name>Erivedge</other_name>
    <other_name>GDC-0449</other_name>
    <other_name>Hedgehog Antagonist GDC-0449</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have histologically or cytologically confirmed sarcoma&#xD;
&#xD;
          -  All Patients must have measurable disease as defined by RECIST 1.1&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 2 (Karnofsky &gt;= 60%)&#xD;
&#xD;
          -  There is a minimum of 1 prior therapy; however, there are no minimum systemic therapy&#xD;
             requirements for well differentiated or de-differentiated liposarcoma, clear cell&#xD;
             sarcoma, chondrosarcoma, alveolar soft part sarcoma and chordomas which have no&#xD;
             effective therapies; for Phase Ib, there are no maximum limits to number of prior&#xD;
             therapies; for Phase II, there is a maximum of 5 prior chemotherapy regimens including&#xD;
             tyrosine kinase inhibitors (TKI); the last dose of systemic therapy (including TKI)&#xD;
             must have been given at least 2 weeks prior to initiation of therapy; patients&#xD;
             receiving nitrosourea (such as BCNU) or mitomycin C must have received their last dose&#xD;
             of such therapy at least 6 weeks prior to initiation of therapy; patients receiving&#xD;
             bevacizumab must wait at least 4 weeks; patients receiving experimental immunotherapy&#xD;
             or antibody based therapies must wait a minimum of 4 weeks or 4 half-lives, whichever&#xD;
             is longer; this should be discussed with the principal investigator before&#xD;
             registration; tumor biopsies should be performed only after meeting these&#xD;
             requirements; patients should recover to less than Common Terminology Criteria for&#xD;
             Adverse Events (CTCAE) grade 2 toxicities related to previous therapies to be eligible&#xD;
&#xD;
          -  Patients with metastatic or locally advanced (inoperable) gastrointestinal stromal&#xD;
             tumor (GIST) must have progressed on imatinib and sunitinib or be intolerant to both&#xD;
             drugs; the last dose of tyrosine kinase inhibitors imatinib or sunitinib should be&#xD;
             given at least 2 weeks prior to initiation of therapy&#xD;
&#xD;
          -  Patients with brain metastasis that have been treated with definitive surgery or&#xD;
             radiation and have been clinically stable for 3 months following the procedure with no&#xD;
             neurological signs or symptoms and no requirement for systemic glucocorticoids are&#xD;
             eligible for study&#xD;
&#xD;
          -  Patients must not have current evidence of another malignancy except non-melanoma skin&#xD;
             cancer and superficial bladder cancer&#xD;
&#xD;
          -  Leukocytes &gt;= 3,000/mcL&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= 1,500/mcL&#xD;
&#xD;
          -  Hemoglobin &gt;= 9 g/dl&#xD;
&#xD;
          -  Platelets &gt;= 100,000/mcL&#xD;
&#xD;
          -  Total bilirubin =&lt; upper limit of normal&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase&#xD;
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])&#xD;
             =&lt; 3 X upper limit of normal&#xD;
&#xD;
          -  Creatinine =&lt; 1.5 or creatinine clearance &gt;= 60 mL/min/1.73 m^2 for patients with&#xD;
             creatinine levels above 1.5&#xD;
&#xD;
          -  Patients treated at Memorial Sloan-Kettering Cancer Center may consent to optional&#xD;
             tumor biopsies before and after initiation of study drug; tumor biopsies should be&#xD;
             obtained after fulfilling requirements&#xD;
&#xD;
          -  Women of child-bearing potential and men must use two forms of contraception (i.e.,&#xD;
             barrier contraception and one other method of contraception) at least 4 weeks prior to&#xD;
             study entry, for the duration of study participation, and for at least 12 months&#xD;
             post-treatment; should a woman become pregnant or suspect she is pregnant while&#xD;
             participating in this study, she should inform her treating physician immediately;&#xD;
             women of childbearing potential are required to have a negative pregnancy test (with a&#xD;
             sensitivity of at least 25 mIU/mL) within 7 days and within 24 hours prior to the&#xD;
             first dose of GDC-0449 and/or RO4929097 (serum or urine); a pregnancy test (serum or&#xD;
             urine) will be administered every 3 weeks to all women of childbearing potential, at&#xD;
             the start of each drug cycle; a positive urine test must be confirmed by a serum&#xD;
             pregnancy test; prior to dispensing GDC-0449 and/or RO4929097, the investigator must&#xD;
             confirm and document the patient's use of two contraceptive methods, dates of negative&#xD;
             pregnancy test, and confirm that patient understands the teratogenic potential of&#xD;
             GDC-0449 and/or RO4929097&#xD;
&#xD;
               -  Female patients of childbearing potential are defined as follows:&#xD;
&#xD;
                    -  Patients with regular menses&#xD;
&#xD;
                    -  Patients, after menarche with amenorrhea, irregular cycles, or using a&#xD;
                       contraceptive method that precludes withdrawal bleeding&#xD;
&#xD;
                    -  Women who have had tubal ligation&#xD;
&#xD;
               -  Female patients may be considered to NOT be of childbearing potential for the&#xD;
                  following reasons:&#xD;
&#xD;
                    -  The patient has undergone total abdominal hysterectomy with bilateral&#xD;
                       salpingo-oophorectomy or bilateral oophorectomy&#xD;
&#xD;
                    -  The patient is medically confirmed to be menopausal (no menstrual period)&#xD;
                       for 24 consecutive months.&#xD;
&#xD;
                    -  The patient is post-menopausal defined by amenorrhea for at least 1 year in&#xD;
                       a woman &gt; 45 years old&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients may not receive other investigational agents within 2 weeks of enrollment in&#xD;
             this study; patients treated with bevacizumab should be off therapy for 4 weeks; other&#xD;
             experimental or immuno therapies should wait for 4 half-lives or 4 weeks, whichever is&#xD;
             longer; prior exposure to Notch or Hedgehog inhibitors is not allowed; patients who&#xD;
             have not recovered to less than CTCAE grade 2 from prior therapies are ineligible&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to GDC-0449 or RO4929097 used in the study&#xD;
&#xD;
          -  Patients taking medications with narrow therapeutic indices that are metabolized by&#xD;
             cytochrome P450 (CYP450), including warfarin sodium (CoumadinÂ®) are ineligible;&#xD;
             patients on warfarin may be considered for enrollment after cessation of warfarin and&#xD;
             appropriate transition to alternate anti-coagulation agents&#xD;
&#xD;
          -  Preclinical studies indicate that RO4929097 is a substrate of cytochrome P450, family&#xD;
             3, subfamily A, polypeptide 4 (CYP3A4) and inducer of CYP3A4 enzyme activity; caution&#xD;
             should be exercised when dosing RO4929097 concurrently with CYP3A4 substrates,&#xD;
             inducers, and/or inhibitors; furthermore, patients who are taking concurrent&#xD;
             medications that are strong inducers/inhibitors or substrates of CYP3A4 should be&#xD;
             switched to alternative medications to minimize any potential risk; the following&#xD;
             medications with strong potential for interaction are not allowed: indinavir,&#xD;
             nelfinavir, ritonavir, clarithromycin, itraconazole, ketoconazole, nefazodone&#xD;
&#xD;
          -  Caution should be exercised when dosing GDC-0449 concurrently with medications that&#xD;
             are substrates of cytochrome P450 family 2, subfamily C, polypeptide 8 (CYP2C8),&#xD;
             CYP2C9, and CYP2C19 and have narrow therapeutic windows; caution should be exercised&#xD;
             when dosing GDC-0449 concurrently with inhibitors of CYP3A4&#xD;
&#xD;
          -  Patients must be able to swallow pills; patients with malabsorption syndrome or other&#xD;
             condition that would interfere with intestinal absorption&#xD;
&#xD;
          -  Patients with clinically active liver disease, including active viral or other&#xD;
             hepatitis or cirrhosis, are ineligible&#xD;
&#xD;
          -  Patients with uncontrolled electrolyte abnormalities including hypophosphatemia,&#xD;
             hypocalcemia, hypomagnesemia, hyponatremia or hypokalemia or defined as less than the&#xD;
             lower limit of normal for the institution, despite adequate electrolyte&#xD;
             supplementation are excluded from this study&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, a history&#xD;
             of torsades de pointes or other significant cardiac arrhythmias that require&#xD;
             antiarrhythmics or other medications known to prolong corrected QT interval (QTc);&#xD;
             psychiatric illness/social situations that would limit compliance with study&#xD;
             requirements&#xD;
&#xD;
          -  Pregnant women are excluded from this study; breastfeeding should be discontinued if&#xD;
             the mother is treated with GDC-0449 and/or RO4929097&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral&#xD;
             therapy are ineligible&#xD;
&#xD;
          -  Cardiovascular: baseline QTc &gt; 450 msec (male) or QTc &gt; 470 msec (female)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mrinal Gounder</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>June 29, 2010</study_first_submitted>
  <study_first_submitted_qc>June 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2010</study_first_posted>
  <results_first_submitted>March 18, 2016</results_first_submitted>
  <results_first_submitted_qc>June 9, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 22, 2016</results_first_posted>
  <last_update_submitted>July 16, 2018</last_update_submitted>
  <last_update_submitted_qc>July 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma, Kaposi</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Osteosarcoma</mesh_term>
    <mesh_term>Rhabdomyosarcoma</mesh_term>
    <mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
    <mesh_term>Sarcoma, Ewing</mesh_term>
    <mesh_term>Neuroectodermal Tumors</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive</mesh_term>
    <mesh_term>Leiomyosarcoma</mesh_term>
    <mesh_term>Liposarcoma</mesh_term>
    <mesh_term>Chondrosarcoma</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive, Peripheral</mesh_term>
    <mesh_term>Sarcoma, Synovial</mesh_term>
    <mesh_term>Hemangiosarcoma</mesh_term>
    <mesh_term>Nerve Sheath Neoplasms</mesh_term>
    <mesh_term>Neurofibrosarcoma</mesh_term>
    <mesh_term>Desmoplastic Small Round Cell Tumor</mesh_term>
    <mesh_term>Fibrosarcoma</mesh_term>
    <mesh_term>Sarcoma, Alveolar Soft Part</mesh_term>
    <mesh_term>Sarcoma, Clear Cell</mesh_term>
    <mesh_term>Hemangioendothelioma</mesh_term>
    <mesh_term>Mesenchymoma</mesh_term>
    <mesh_term>Dermatofibrosarcoma</mesh_term>
    <mesh_term>Hemangioendothelioma, Epithelioid</mesh_term>
    <mesh_term>Histiocytoma, Malignant Fibrous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>R04929097</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>RO4929097 10mg</title>
          <description>RO4929097: 10mg PO QD, GDC-0449: 150 mg PO QD</description>
        </group>
        <group group_id="P2">
          <title>RO4929097 15 mg</title>
          <description>RO4929097: 15 mg PO QD, GDC-0449: 150 mg PO QD</description>
        </group>
        <group group_id="P3">
          <title>ARM 1 - RO4929097: 15 mg PO QD</title>
          <description>ARM 1 - RO4929097: 15 mg PO QD</description>
        </group>
        <group group_id="P4">
          <title>ARM 2: GDC-0449 150 mg PO QD and RO4929097 15 mg PO QD</title>
          <description>ARM 2: GDC-0449 150 mg PO QD and RO4929097 15 mg PO QD</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Phase Ib</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not Treated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Phase II</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="35"/>
                <participants group_id="P4" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="30"/>
                <participants group_id="P4" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>RO4929097 10mg</title>
          <description>RO4929097: 10mg PO QD, GDC-0449: 150 mg PO QD</description>
        </group>
        <group group_id="B2">
          <title>RO4929097 15 mg</title>
          <description>RO4929097: 15 mg PO QD, GDC-0449: 150 mg PO QD</description>
        </group>
        <group group_id="B3">
          <title>ARM 1 - RO4929097: 15 mg PO QD</title>
          <description>ARM 1 - RO4929097: 15 mg PO QD</description>
        </group>
        <group group_id="B4">
          <title>ARM 2: GDC-0449 150 mg PO QD and RO4929097 15 mg PO QD</title>
          <description>ARM 2: GDC-0449 150 mg PO QD and RO4929097 15 mg PO QD</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="35"/>
            <count group_id="B4" value="33"/>
            <count group_id="B5" value="78"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="33"/>
                    <measurement group_id="B5" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum-tolerated Dose of Gamma-secretase Inhibitor RO4929097, Defined as the Dose Level Where no More Than 1 Out of 6 Patients Experience DLT at the Highest Dose Level Below the MAD, Graded According to NCI-CTCAE Version 4.0 (Phase Ib)</title>
        <time_frame>Up to 28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Phase Ib Participants</title>
            <description>All Phase Ib Participants</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum-tolerated Dose of Gamma-secretase Inhibitor RO4929097, Defined as the Dose Level Where no More Than 1 Out of 6 Patients Experience DLT at the Highest Dose Level Below the MAD, Graded According to NCI-CTCAE Version 4.0 (Phase Ib)</title>
          <units>mg</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival (PFS)</title>
        <description>Progression-free survival (PFS) of the combination of RO4929097 with and without GDC-0449 in patients with advanced sarcoma. (Phase II)</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Gamma-secretase Inhibitor RO4929097)</title>
            <description>Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO QD on days 1-21.&#xD;
Gamma-Secretase Inhibitor RO4929097: Given PO&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Pharmacological Study: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Vismodegib and Gamma-secretase Inhibitor RO4929097)</title>
            <description>Patients receive vismodegib PO and gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO QD on days 1-21.&#xD;
Gamma-Secretase Inhibitor RO4929097: Given PO&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Pharmacological Study: Correlative studies&#xD;
Vismodegib: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS)</title>
          <description>Progression-free survival (PFS) of the combination of RO4929097 with and without GDC-0449 in patients with advanced sarcoma. (Phase II)</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Rate (CR + PR) as Assessed by RECIST 1.1 (Phase Ib and II)</title>
        <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions</description>
        <time_frame>Up to 4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RO4929097 10mg</title>
            <description>RO4929097: 10mg PO QD, GDC-0449: 150 mg PO QD</description>
          </group>
          <group group_id="O2">
            <title>RO4929097 15 mg</title>
            <description>RO4929097: 15 mg PO QD, GDC-0449: 150 mg PO QD</description>
          </group>
          <group group_id="O3">
            <title>ARM 1 - RO4929097: 15 mg PO QD</title>
            <description>ARM 1 - RO4929097: 15 mg PO QD</description>
          </group>
          <group group_id="O4">
            <title>ARM 2: GDC-0449 150 mg PO QD and RO4929097 15 mg PO QD</title>
            <description>ARM 2: GDC-0449 150 mg PO QD and RO4929097 15 mg PO QD</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate (CR + PR) as Assessed by RECIST 1.1 (Phase Ib and II)</title>
          <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Stable Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progression of Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>RO4929097 10mg</title>
          <description>RO4929097: 10mg PO QD, GDC-0449: 150 mg PO QD</description>
        </group>
        <group group_id="E2">
          <title>RO4929097 15 mg</title>
          <description>RO4929097: 15 mg PO QD, GDC-0449: 150 mg PO QD</description>
        </group>
        <group group_id="E3">
          <title>ARM 1 - RO4929097: 15 mg PO QD</title>
          <description>ARM 1 - RO4929097: 15 mg PO QD</description>
        </group>
        <group group_id="E4">
          <title>ARM 2: GDC-0449 150 mg PO QD and RO4929097 15 mg PO QD</title>
          <description>ARM 2: GDC-0449 150 mg PO QD and RO4929097 15 mg PO QD</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Retroperitoneal hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Prostate infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Treatment related secondary malignancy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Tumor pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Resp, thoracic &amp; mediastinal disorder Other, spec</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="42" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E3" events="56" subjects_affected="11" subjects_at_risk="35"/>
                <counts group_id="E4" events="32" subjects_affected="8" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="12" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E3" events="32" subjects_affected="6" subjects_at_risk="35"/>
                <counts group_id="E4" events="5" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E4" events="3" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="6" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="20" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E4" events="6" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="7" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>CPK increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E3" events="34" subjects_affected="6" subjects_at_risk="35"/>
                <counts group_id="E4" events="10" subjects_affected="5" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="18" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E3" events="21" subjects_affected="9" subjects_at_risk="35"/>
                <counts group_id="E4" events="16" subjects_affected="4" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="13" subjects_affected="7" subjects_at_risk="35"/>
                <counts group_id="E4" events="3" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="26" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E3" events="50" subjects_affected="14" subjects_at_risk="35"/>
                <counts group_id="E4" events="26" subjects_affected="12" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal &amp; conn tissue disorder Other, spec</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Muscle weakness upper limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Roche has discontinued further development of the Notch inhibitor (RO4929097) and this Phase II trial was prematurely closed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Mrinal Gounder</name_or_title>
      <organization>Memorial Sloan Kettering Cancer Center</organization>
      <phone>646-888-4167</phone>
      <email>gounderm@mskcc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

